Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599642 | 0.84 | KMT2A (0.66) | KMT2ARAB9AMAPTSMN1; SMN2AKR1B1 | |
| SCHEMBL11774212 | 0.78 | POLB (0.59) | KMT2ARAB9AMAPTSMN1; SMN2AKR1B1 | |
| SCHEMBL14499599 | 0.78 | KMT2A (0.72) | KMT2ASMN1; SMN2ALDH1A1L3MBTL1FPR2 | |
| SCHEMBL24980367 | 0.77 | AKR1B1 (0.63) | KMT2ASMN1; SMN2AKR1B1ALDH1A1NPC1 | |
| SCHEMBL10304450 | 0.77 | POLB (0.62) | KMT2ARAB9AMAPTSMN1; SMN2AKR1B1 | |
| SCHEMBL19002339 | 0.74 | LMNA (0.60) | KMT2ARAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11495079 | 0.74 | POLB (0.54) | KMT2ARAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18356377 | 0.73 | KMT2A (0.76) | KMT2ARAB9AMAPTSMN1; SMN2AKR1B1 | |
| SCHEMBL11808078 | 0.73 | KMT2A (0.63) | KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11638327 | 0.72 | HSD17B10 (0.57) | KMT2ARAB9AMAPTSMN1; SMN2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | KMT2A 1629/4885RAB9A 3025/4885MAPT 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.